Results 1 to 2 of 2 matches
Category 6 - PATHOLOGY SERVICES
Detection of measurable residual disease in patients with acute lymphoblastic leukaemia (MBS items 71202 and 73310)
Category 6 - PATHOLOGY SERVICES
73310 - Additional Information
Item Start Date:
01-Nov-2023
Description Updated:
01-Nov-2023
Schedule Fee Updated:
01-Nov-2023
Group
P7 - Genetics
Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist
Fee: $1,550.00 Benefit: 75% = $1,162.50 85% = $1,447.60
(See para PN.0.35 of explanatory notes to this Category)
Results 1 to 2 of 2 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change